We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
PD-L1 expression and response to pembrolizumab in patients with EGFR-mutant non-small cell lung cancer.
- Authors
Miyawaki, Eriko; Murakami, Haruyasu; Mori, Keita; Mamesaya, Nobuaki; Kawamura, Takahisa; Kobayashi, Haruki; Omori, Shota; Wakuda, Kazushige; Ono, Akira; Kenmotsu, Hirotsugu; Naito, Tateaki; Takahashi, Toshiaki
- Abstract
Epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer is less likely to express programmed death-ligand 1 (PD-L1) than tumors with wild-type EGFR and is associated with poor response to pembrolizumab. To understand the relationship between EGFR mutation and PD-L1 expression in pembrolizumab response, we retrospectively evaluated the factors contributing to the high tumor proportion score in 155 EGFR -mutant non-small cell lung cancer cases and their associated response to pembrolizumab. Uncommon EGFR mutations were significantly associated with a PD-L1 tumor proportion score ≥ 50% compared to common EGFR mutations. The objective response rate to pembrolizumab of 14 patients was 36%, including 22% in patients with common EGFR mutations, 60% in patients with uncommon EGFR mutations and 75% in patients with both uncommon mutations and a PD-L1 tumor proportion score ≥ 50%. A PD-L1 tumor proportion score ≥ 50% was more frequent in non-small cell lung cancer patients harboring uncommon EGFR mutations and was associated with pembrolizumab efficacy.
- Publication
Japanese Journal of Clinical Oncology, 2020, Vol 50, Issue 5, p617
- ISSN
0368-2811
- Publication type
Article
- DOI
10.1093/jjco/hyaa033